Avacta Group (AVCT) Competitors

GBX 48.80
+3.80 (+8.44%)
(As of 04/26/2024 ET)

AVCT vs. 4BB, HVO, FUM, OXB, SCLP, FARN, BVXP, POLB, ETX, and TRX

Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include 4basebio (4BB), hVIVO (HVO), Futura Medical (FUM), Oxford Biomedica (OXB), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), Bioventix (BVXP), Poolbeg Pharma (POLB), e-therapeutics (ETX), and Tissue Regenix Group (TRX). These companies are all part of the "biotechnology" industry.

Avacta Group vs.

4basebio (LON:4BB) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.

9.1% of 4basebio shares are owned by institutional investors. Comparatively, 8.8% of Avacta Group shares are owned by institutional investors. 62.2% of 4basebio shares are owned by insiders. Comparatively, 29.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

4basebio has higher earnings, but lower revenue than Avacta Group. 4basebio is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£311K440.73-£6.28M-£0.51-2,098.04
Avacta Group£16.02M10.68-£42.08M-£0.16-305.00

In the previous week, Avacta Group's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
4basebio Neutral
Avacta Group Neutral

Avacta Group received 212 more outperform votes than 4basebio when rated by MarketBeat users.

CompanyUnderperformOutperform
4basebioN/AN/A
Avacta GroupOutperform Votes
212
67.30%
Underperform Votes
103
32.70%

4basebio has a net margin of 0.00% compared to 4basebio's net margin of -267.00%. Avacta Group's return on equity of -97.29% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -97.29% -35.08%
Avacta Group -267.00%-143.33%-26.00%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

4basebio has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Avacta Group has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Summary

4basebio and Avacta Group tied by winning 6 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVCT vs. The Competition

MetricAvacta GroupBiotechnology IndustryMedical SectorLON Exchange
Market Cap£171.05M£176.63M£4.87B£1.44B
Dividend Yield3.97%3.48%2.96%11.90%
P/E Ratio-305.00236.59227.841,797.62
Price / Sales10.6813,765.782,284.76304,583.14
Price / Cash15.0011.3046.7627.04
Price / Book6.105.474.762.55
Net Income-£42.08M-£30.32M£103.21M£185.94M
7 Day Performance0.62%1.16%0.81%18.73%
1 Month Performance-4.13%-3.11%-6.14%8.87%
1 Year Performance-61.21%48.89%9.81%13.08%

Avacta Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
4BB
4basebio
0 of 5 stars
GBX 1,045
flat
N/A+71.0%£133.86M£311,000.00-2,049.0278Gap Up
HVO
hVIVO
0 of 5 stars
GBX 28.25
+2.7%
N/A+77.6%£192.21M£60.48M-1.00N/APositive News
FUM
Futura Medical
0 of 5 stars
GBX 35.55
-0.1%
N/A-29.2%£107.17M£1.70M-1,777.5012Gap Up
OXB
Oxford Biomedica
0.8876 of 5 stars
GBX 215
+1.2%
GBX 498.75
+132.0%
-51.3%£214.91M£119.02M-335.94891High Trading Volume
SCLP
Scancell
0 of 5 stars
GBX 9.60
flat
N/A-40.1%£89.07M£5.27M-960.0051
FARN
Faron Pharmaceuticals Oy
0 of 5 stars
GBX 127.50
+6.3%
N/A-59.1%£87.73M£-725,000.00-303.5734
BVXP
Bioventix
0 of 5 stars
GBX 4,475
-1.1%
N/A+16.3%£233.60M£13.60M2,745.4012
POLB
Poolbeg Pharma
0 of 5 stars
GBX 10.55
+3.4%
N/A+55.9%£52.75MN/A-1,055.0012
ETX
e-therapeutics
0 of 5 stars
GBX 8.85
-13.7%
N/A-32.6%£51.71M£295,000.00-442.5034Gap Down
High Trading Volume
TRX
Tissue Regenix Group
0 of 5 stars
GBX 61.50
flat
N/A+9,982.0%£43.40M£29.49M-3,075.0082

Related Companies and Tools

This page (LON:AVCT) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners